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Abstract
Protease-activated receptor-2 (PAR2) is a G protein coupled receptor (GPCR) activated by proteolytic cleavage of its amino
terminal domain by trypsin-like serine proteases. This irreversible activation mechanism leads to rapid receptor
desensitization by internalisation and degradation. We have explored the role of palmitoylation, the post-translational
addition of palmitate, in PAR2 signalling, trafficking, cell surface expression and desensitization. Experiments using the
palmitoylation inhibitor 2-bromopalmitate indicated that palmitate addition is important in trafficking of PAR2
endogenously expressed by prostate cancer cell lines. This was supported by palmitate labelling using two approaches,
which showed that PAR2 stably expressed by CHO-K1 cells is palmitoylated and that palmitoylation occurs on cysteine 361.
Palmitoylation is required for optimal PAR2 signalling as Ca
2+ flux assays indicated that in response to trypsin agonism,
palmitoylation deficient PAR2 is ,9 fold less potent than wildtype receptor with a reduction of about 33% in the maximum
signal induced via the mutant receptor. Confocal microscopy, flow cytometry and cell surface biotinylation analyses
demonstrated that palmitoylation is required for efficient cell surface expression of PAR2. We also show that receptor
palmitoylation occurs within the Golgi apparatus and is required for efficient agonist-induced rab11a-mediated trafficking
of PAR2 to the cell surface. Palmitoylation is also required for receptor desensitization, as agonist-induced b-arrestin
recruitment and receptor endocytosis and degradation were markedly reduced in CHO-PAR2-C361A cells compared with
CHO-PAR2 cells. These data provide new insights on the life cycle of PAR2 and demonstrate that palmitoylation is critical for
efficient signalling, trafficking, cell surface localization and degradation of this receptor.
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Introduction
Protease-activated receptors (PARs) are a subfamily of class A G
protein-coupled receptors (GPCRs) consisting of four members,
designated PAR1-4. Unlike other GPCRs which are activated by
reversible binding of soluble ligand, these receptors are irreversibly
activated by proteases; almost exclusively members of the trypsin-
fold serine protease family. Proteolytic cleavage within the PAR
extracellular amino terminal domain exposes a new amino
terminus, or tethered ligand, which binds intramolecularly to
induce intracellular signal transduction [1,2].
The second PAR discovered, PAR2, is widely expressed and is
thought to contribute to a range of normal and disease processes
including embryogenesis, pain and nociception, acute and chronic
inflammation, arthritis and cancer [3,4,5,6,7,8]. PAR2 is activated
by numerous trypsin-like serine proteases including trypsin, mast
celltryptase,tissuefactorcomplexedwithfactorVIIa and factorXa,
and kallikrein 4, 5, 6 and 14 [9,10,11,12,13]. As for PAR1 and
PAR4, PAR2 can also be activated by hexapeptides, termed agonist
peptides (AP), that mimic the tethered ligand. Cell surface
expression of PAR2 enables the cell to respond normally or
aberrantly to protease challenge by inducing signal transduction via
coupled hetrotrimeric G protein subunits Gaq,G ai and Ga12/13 to
elicit mitogen-activated protein kinase (MAPK) signalling, calcium
mobilisation, Rho and RacactivationandstimulationofNF-kBa n d
gene transcription [1]. PAR2 also signals independent of G proteins
via b-arrestin mediated activation of the MAPK pathway [14].
Due to the irreversible nature of PAR2 activation, rapid
mechanisms are required to prevent sustained and excessive
receptor signalling. Following proteolysis, PAR2 is phosphorylated
within the carboxyl terminus and ubiquitinated on intracellular
lysine residues before interacting with b-arrestins enabling
receptor desensitisation and internalisation [15,16]. PAR2 is
trafficked via the early and late endosomes and degraded within
lysosomes [17,18]. A consequence of irreversible activation and
rapid desensitisation and degradation, is that large intracellular
PAR2 stores are required to rapidly replenish the cell surface with
nascent receptors thereby re-establishing the ability of cells to sense
proteolytic activity. Although the mechanisms controlling this
process are poorly characterised, it is clear that the GTPase
rab11a participates in intracellular trafficking of PAR2 within the
Golgi apparatus and toward the plasma membrane [19].
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phorylation and ubiquitination of PAR2 are critical regulators of
PAR2 function [15,16,20]. Recently, Botham and colleagues have
also shown that PAR2 is modified by the post-translation addition
of palmitate to cysteine 361 (C361) [21]. Palmitoylation is often
dynamic and reversible and occurs commonly for GPCRs on one
or more carboxyl terminal cysteines found 10 to 14 residues
following the seventh transmembrane domain [22]. In addition to
these thioester linkages (so called S-palmitoylation), there are a
small number of examples where palmitate addition to cysteine is
followed by structural rearrangement leading to palmitate
modification of an amide (N-palmitoylation) [23]. Palmitoylation
anchors the GPCR carboxyl domain to the inner leaflet of cell
membranes resulting in the formation of an intracellular eighth a-
helix (H8) and has diverse effects on GPCR function including
regulation of cellular trafficking [24,25]. It is also proposed to
regulate GPCR signalling by modifying the conformation of the
carboxyl terminus thereby impacting on G protein coupling
[26,27,28].
Here we report on the role of palmitoylation in regulating cell
surface expression of endogenous PAR2 and use stably and
transiently expressing cells to explore the function of this
modification in receptor trafficking, signalling and degradation.
In contrast with Botham and co-workers, who show that
palmitoylation deficient PAR2 stably expressed by CHO-Pro5
cells is more highly expressed on the cell surface than wildtype
receptor [21], we demonstrate that palmitoylation of PAR2 is
required for efficient plasma membrane receptor expression in 3
different endogenously expressing cell lines. Our data from these
cell lines are supported by detailed studies comparing CHO-K1
cells stably expressing wildtype or C361A PAR2. We also explore
the role of receptor agonism in PAR2 palmitoylation and how this
post-translational modification regulates rab11a trafficking to the
cell surface, agonist induced b-arrestin relocation to the cell
surface and receptor degradation. Our data suggest that S-
palmitoylation is required for optimal PAR2 signalling, cellular
trafficking and plasma membrane localization.
Methods
Antibodies and reagents
Anti-PAR2 antibody N19 was from Santa Cruz Biotechnology
(Quantum Scientific Pty Ltd, Murarrie, Australia) and an anti-myc
epitope (EQKLISEEDL) antibody was from Cell Signaling
Technology (Genesearch Pty Ltd, Arundel, Australia). An anti-
GAPDH antibody was from Sigma Aldrich (Castle Hill, Australia).
Alexa Fluor 680-conjugated streptavidin and Alexa Fluor 488-,
Alexa Fluor 647- and Alexa Fluor 680-conjugated secondaries
were from Invitrogen (Mulgrave, Australia) and IRdye 800-
conjugated secondary antibodies were from LiCor (Millennium
Science, Surrey Hills, Australia). PAR2 activating peptide (AP;
SLIGRL-NH2) was purchased from Auspep (Parkville, Australia).
Active bovine trypsin was obtained from Worthington Biochem-
ical (Scimar Pty Ltd, Templestowe, Australia). N-glycosidase F was
purchased from New England Biolabs (Genesearch Pty Ltd).
Brefeldin A, 2-bromopalmitate, cerulenin, CuSO4 III, cyclohex-
imide, hydroxylamine, MG132, monensin, N-ethylmaleimide
(NEM), nocodazole, palmitate, sodium fluoride, sodium vanadate,
t-butanol, tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl] amine
(TBTA) and tris(2-carboxyethyl)phosphine (TCEP) were from
Sigma Aldrich. 17-Octadecynoic acid (17-ODYA) was from
Cayman Chemicals (Sapphire Bioscience, Waterloo, Australia)
and biotin-azide and Fura-2 were purchased from Invitrogen. EZ-
link NHS-SS-biotin and EZ-link HPDP-biotin were from Pierce
(Thermo Fisher Scientific, Scoresby, Australia). Protease inhibitor
cocktail was purchased from Roche (Castle Hill, Australia). Live
cell imaging 8 chamber m-slides were obtained from Ibidi (In Vitro
Technologies Pty Ltd, Noble Park, Australia). Protein concentra-
tions were determined using a bicinchoninic acid assay (BCA) kit
from Pierce.
Expression constructs and mutagenesis
The human PAR2 open reading frame incorporating 39
sequence encoding a carboxyl terminal myc epitope (sequence)
was amplified by PCR using Expand High Fidelity polymerase
mixture (Roche) from a previously described construct [12] and
cloned into the pIRESneo2 vector (Clonetech, Scientifix Pty Ltd,
Clayton, Australia). Site-directed mutagenesis, to mutate this
PAR2-myc construct at cysteine 361 to alanine (C361A) was
performed using Pfu Ultra polymerase (Agilent Technologies,
Forest Hill, Australia). A construct encoding PAR2 tagged at the
carboxyl terminal with green fluorescent protein (GFP) was
described previously [12]. An expression construct encoding
PAR2 with a carboxyl terminal monomeric Cherry (mCherry)
was generated from the PAR2-GFP construct. The GFP encoding
fragment was removed from PAR2-GFP by restriction digestion
using BamHI and NotI (New England Biolabs) and this was
replaced with mCherry encoding DNA [29]. The sequence of all
constructs was confirmed by DNA sequencing at the Australian
Genome Research Facility (St. Lucia, Australia). Expression
constructs encoding amino terminal GFP tagged wildtype Rab11a
and dominant negative mutant Rab11a-S25N were from Dr
Marci Scidmore (Cornell University) [30]. Expression constructs
encoding carboxyl terminal GFP tagged b-arrestin-1 & -2 were
from Dr Robert Lefkowitz (Duke University Medical Center) [31].
Cell culture and transfections
All cell culture media and reagents were from Invitrogen except
for fetal calf serum which was from Sigma Aldrich. Cells were
purchased from ATCC (Manassas, VA). Chinese hamster CHO-
K1 (CHO) cells were grown in DMEM and prostate cancer lines
PC3, DU145 and 22Rv1 were grown in RPMI1640 medium,
supplemented with 10% fetal calf serum (FCS), 100 units/ml of
penicillin, and 100 units/ml of streptomycin in a 5% CO2
humidified atmosphere at 37uC. All cells were passaged using
0.5 mM EDTA in PBS. Transfections were performed using
either Lipofectamine 2000 or Lipofectamine LTX (Invitrogen).
For stable transfections CHO cells were transfected with
pIRESneo2 (vector), PAR2-myc or PAR2-C361A-myc using
Lipofectamine 2000 then selected in G418 (800 mg/ml) containing
media for 10 days before clones were selected for expansion and
characterisation.
Cell membrane preparation
Crude cell membrane extracts were collected as previously
described [32] with some alterations. Briefly, cells at 50%
confluence were washed with PBS and distilled H2O for 30 sec
to induce hyptonic cell shock. Swollen cells were mechanically
resuspended in membrane buffer (5 mM Tris, pH 7.5, 0.5 mM
EDTA, 16 protease inhibitor cocktail, 1 mM sodium vanadate
and 10 mM sodium fluoride) and disrupted by several passes
through a 26 gauge needle. Cellular debris was removed by
centrifugation (800 g for 10 min at 4uC). Crude membrane
preparations were collected from the supernatant by ultracentri-
fugation (100,000 g for 1 h at 4uC) then resuspended in lysis buffer
containing 50 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA,
1% Triton X-100 (v/v) and 16protease inhibitor cocktail (Roche)
before protein quantification using a BCA kit (Pierce).
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PAR2 palmitoylation was assessed by an acyl-biotinyl exchange
approach (ABE; [33]) described previously [34]. Crude membrane
extracts, isolated as above, were prepared from cells at 50%
confluence. To assess the effect of PAR2 agonism on palmitoyla-
tion, before isolation of cell membranes cells were treated with
PAR2 AP (100 mM). To prevent protein palmitoylation, cells were
incubated with 2-bromopalmitate for 16 h prior to collection of
crude membrane. Membrane pellets were solubilised for 1 h at
4uC in lysis buffer containing 50 mM HEPES pH 7.4, 150 mM
NaCl, 5 mM EDTA, 1% Triton X-100 (v/v), 16 protease
inhibitor cocktail (Roche) and, to block free thiols, 10 mM NEM.
Solubilized protein (100 mg) was chloroform-methanol (1:3:2
protein:methanol:chloroform; CM) precipitated and protein
pellets were resuspended in a buffer containing 4% SDS (4SB;
4% SDS, 50 mM HEPES pH 7.4, 5 mM EDTA) and diluted five
fold with lysis buffer containing 10 mM NEM and incubated at
4uC overnight with gentle agitation. Excess NEM was removed by
three sequential CM precipitations followed by resuspension in
4SB (50 ml). Samples were divided into two equal portions. To
cleave thioester bonds and allow incorporation of a biotin moiety
at exposed sulphur atoms, one portion was diluted five fold in
buffer (0.2% Triton X-100, 16 protease inhibitor cocktail)
containing hydroxylamine (0.7 M) and EZ-link HPDP-biotin
(1 mM). As a control the other portion was diluted five fold in
the same buffer in which hydroxylamine was replaced with Tris
(50 mM Tris pH 7.4). In the absence of hydroxylamine, palmitate
groups are not removed thereby preventing biotinylation mediated
purification. Each portion was incubated at ambient temperature
for 1 h with gentle agitation. Unreacted biotin was removed by
three sequential CM precipitations and the protein pellet was
resuspended in 4SB and diluted 10 fold in Tris containing lysis
buffer. Biotinylated proteins were affinity purified using strepta-
vidin beads (Pierce) by incubation at 4uC for 1 h. Bound proteins
were eluted from washed beads with SDS sample buffer and
subjected to denaturing polyacrylamide gel electrophoresis (SDS-
PAGE). Palmitoylated PAR2 was detected by anti-myc Western
blot analysis.
Analysis of palmitoylation by metabolic labelling with an
alkyne containing palmitate analogue followed by in
vitro copper catalysed alkyne-azide cycloaddition (click)
chemistry
PAR2 palmitoylation was also examined using a modified
version of a recently described method using an alkyne containing
palmitate analog (17-ODYA) reacted to biotin-azide via click
chemistry [35]. To inhibit endogenous palmitate synthesis cells
were preincubated for 1 h at 37uC with cerulenin (5 mg/mL),
before metabolic labelling with the palmitate analog 17-ODYA
(25 mM) for 2 h at 37uC. To assess the effect of PAR2 agonism on
palmitoylation, cells were labelled with 17-ODYA in the presence
or absence of PAR2 AP (100 mM). To examine PAR2 palmitoyla-
tion in particular organelles, cells were labelled with 17-ODYA for
2 h in the presence of protein trafficking and organelle function
inhibitors: Brefeldin A (5 mg/mL; blocks ER-to-Golgi protein
traffic [36]), nocodazole (20 mg/mL; blocks ER-to-pre-Golgi
protein traffic [37]), monensin (10 mM; blocks medial-Golgi-to-
post-Golgi traffic [36]), and 2-bromopalmitate (100 mM; inhibits
protein palmitoylation [38]). Nocodazole was added to cells
15 min before labelling with 17-ODYA, while Brefeldin A,
monensin and MG132 were added 30 min prior to labelling with
17-ODYA. 2-Bromopalmitate was incubated with cells for 16 h
before collection of membrane fractions. Crude membrane
fractions, isolated as described above, were CM precipitated then
resuspended in PBS containing 1.2% SDS by sonication and
heating at 70uC for 10 min. Proteins (100 mg at 1 mg/mL)
labelled with alkyne containing 17-ODYA were reacted with
biotin-azide via standard click chemistry conditions; involving the
addition of 100 mM biotin-azide (1 mM stock dissolved in
DMSO), 1 mM TCEP (50 mM stock dissolved in H2O),
100 mM TBTA (1.7 mM stock dissolved in 20% DMSO/80% t-
butanol) and 1 mM CuSO4 (50 mM stock dissolved in PBS) in
order, followed by incubation in the dark at ambient temperature
for 1 h. Samples were CM precipitated to remove excess biotin,
resuspended in PBS containing 0.8% SDS and diluted eight fold in
lysis buffer. Palmitoylated proteins modified with a biotin moiety
were affinity purified using streptavidin beads by incubation at
4uC for 1 h with gentle agitation. Bound proteins were eluted from
washed beads with SDS sample buffer and subjected to SDS-
PAGE followed by anti-myc Western blot analysis to detect
palmitoylated PAR2. In experiments to assess whether palmitoyla-
tion was found exclusively on cysteines and not at amids, samples
were boiled in 0.7 M hydroxylamine (to cleave thioester bonds) or
50 mM Tris pH 7.4 (control) prior to immobilisation on
streptavidin beads.
Cell surface biotinylation
Cell surface proteins were isolated using cell impermeant EZ-
link NHS-SS-biotin (1.22 mg/mL) as described previously [39].
Briefly, cells at 50% confluence stably transfected with PAR2-myc,
PAR2-C361A-myc or vector were washed with PBS and
biotinylated for 1 h at 4uC. Cells were washed with PBS and
whole cell lysates collected in lysis buffer (1% (v/v) Triton X-100,
50 mM Tris/HCl (pH 7.4), 150 mM NaCl and 16 protease
inhibitor cocktail). After removal of cellular debris by centrifuga-
tion (3000 rpm for 10 min at 4uC), lysates were incubated with
streptavidin beads (Pierce) for 30 min at 4uC with gentle agitation.
Biotinylated cell surface proteins immobilised on streptavidin
beads were pelleted by centrifugation (3000 rpm for 5 min at 4uC)
and together with intracellular proteins present in the supernatant
were examined by Western blot analysis.
Receptor endocytosis
PAR2 endocytosis was assessed as previously described [40].
Briefly, cell surface proteins were labelled with cell impermeant
EZ-link NHS-SS-biotin (0.5 mg/mL) for 30 min at 4uC, then
washed before incubation at 37uC in culture media containing
PAR2 AP (100 mM) and MG132 (20 mM) for 5, 15 and 30 min to
allow receptor internalisation. Surface biotin was removed by
incubating cells at 4uC in reducing buffer (50 mM 2-mercap-
toethanesulfonic acid sodium salt (MeSNA), 100 mM Tris pH 8.6,
100 mM NaCl) for 30 min before excess MeSNA was quenched
with 60 mM iodoacetamide for 15 min in PBS. Whole cell lysates
were collected in lysis buffer and incubated with streptavidin beads
to isolate internalised PAR2 which was examined by Western blot
analysis.
Western blot analysis
Whole cell lysates collected in lysis buffer, cell membrane
preparations, proteins eluted from streptavidin beads, and proteins
collected from the cell surface biotinylation protocol were
separated by SDS/PAGE and transferred to nitrocellulose
membranes. After blocking with Odyssey blocking buffer (LiCor),
membranes were incubated with primary antibodies overnight at
4uC, washed and then incubated with species-appropriate
AlexaFluor 680 or IRdye 800-conjugated secondary antibodies
Palmitoylation of PAR2
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branes were scanned on an Odyssey infrared imaging system
(LiCor). Consistent protein loading and transfer was determined
by reprobing membranes with either an anti-GAPDH antibody or
AlexaFluor-680-conjugated streptavidin. Where relevant, signal
intensity was determined by densitometry analysis using Odyssey
software (LiCor).
Flow cytometry
Adherent cells at 50% confluence were lifted non-enzymatically,
counted and 2.5610
5 cells were washed and stained with goat
anti-PAR2 antibody N19 (2 mg/1610
6 cells) in PBS containing
2% FCS for 30 min at 4uC. After washing with PBS, cells were
stained with an AlexaFluor 488-conjugated secondary antibody
(Invitrogen) and 20,000 events were collected and analysed on a
Beckman Coulter FC500 flow cytometer. For cell surface
repopulation experiments, resuspended cells treated with 50 nM
trypsin for 15 min at 37uC were washed then incubated in trypsin-
free DMEM for 0, 15 and 30 min and placed on ice, followed by
staining with anti-PAR2 N19 antibody. For cells expressing GFP,
a donkey anti-goat Alexa Fluor 647-conjugated secondary
antibody was used to prevent spectral overlap and cells were
analysed on a Beckman Coulter CyAN flow cytometer. For all
experiments, mean fluorescence intensity (MFI) values were
calculated by subtracting secondary only staining from specific
anti-PAR2 staining.
Calcium mobilisation assay
Analysis of calcium mobilisation was performed as previously
described [12]. Cells at 50% confluence lifted nonenzymatically
Figure 1. Inhibition of palmitoylation reduces cell surface expression of endogenous PAR2. A, Upper panel; schematic representation of
the structure of human PAR2 including the tethered ligand sequence (underline) within the amino terminal domain, C361 within a consensus
palmitoylation motif present in carboxyl terminal domain, seven transmembrane (TM1 to TM7) domains, and a disulfide bond linking TM3 and the
second extracellular loop (dotted line). Lower panel; protein sequence alignment of seventh transmembrane and carboxyl terminal residues of
arginine vasopressin receptor-2 (V2R; NM_000054; residues 329–371), b2-adrenergic receptor (b2R; NM_000024.5; residues 329–413), PAR1
(NM_001992.3; residues 375–425), PAR2 (NM_005242.4; residues 347–397), PAR3 (NM_004101.2; residues 362–374) and PAR4 (NM_003950.2; residues
344–385). The known palmitoylation sites of V2R and b2R and the consensus palmitoylation sites of PAR1 and PAR2 are boxed. B, Western blot
analysis of lysates from CHO cells stably transfected with vector or PAR2-myc probed with anti-PAR2 antibodies N19 and SAM11 and anti-myc and
anti-GAPDH antibodies. *, non-specific band. C, Anti-PAR2 flow cytometry analysis of non-permeabilised CHO cells stably transfected with vector or
PAR2-myc using antibodies N19 and SAM11. MFI values: CHO-PAR2 cells with N19 51.962.5; CHO-PAR2 cells with SAM11 41.663.2; signal from
incubation of CHO-PAR2 cells with secondary antibody (2u), CHO-vector with antibody N19 (Vector N19) and CHO-vector with antibody SAM11
(Vector SAM11) were below 10
0. D, Flow cytometry analysis of cell surface PAR2 endogenously expressed by non-permeabilised PC-3 cells using anti-
PAR2 N19 and SAM11 antibodies. MFI values: N19 4.360.5; SAM11 2.360.9; secondary antibody (2u) 0.6060.06. E, Graphical representation of the
effect of blocking palmitoylation on cell surface expression of PAR2. Plasma membrane levels of PAR2, expressed endogenously by PC3, DU145 and
22Rv1 cells, were determined by flow cytometry using the anti-PAR2 N19 antibody. Non-permebilised cells were either treated with DMSO (negative
control) or 2-bromopalmitate (+2BP) for 16 h. Secondary antibody only MFI values were subtracted from N19 values before calculation of the level of
cell surface PAR2 present on 2BP treated cells relative to DMSO treated cells. Values were determined from 3 independent experiments and are
shown as mean 6 SD. **, P,0.001.
doi:10.1371/journal.pone.0028018.g001
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ester (1 mM; Invitrogen) for 1 h at 37uC in buffer containing
25 mM HEPES pH 7.4, 121 mM NaCl, 5.4 mM KCl, 0.8 mM
MgCl2, 1.8 mM CaCl2, 5.5 mM glucose, 2.5 mM probenecid and
0.01% (v/v) pluronic acid. Cells were washed with PBS and
resuspended in the same buffer lacking Fura-2 and pluoronic acid.
A range of 0.1–1000 nM trypsin was used for dose-response
experiments. Calcium mobilisation was monitored using a
Polarstar Optima fluorescent plate reader (BMG Labtech Pty
Ltd, Mornington, Australia). All experiments were performed in
triplicate on three independent occasions with results displayed as
mean 6 SD normalised to maximal PAR2 response.
Live cell Confocal microscopy
Cells seeded in 8 chamber m-slides (Ibidi) were transiently co-
transfected with GFP and mCherry containing expression con-
structs for 12 h and imaged at 37uC in a 5% CO2 atmosphere using
a Zeiss LSM510 confocal microscope. Images were processed using
MetaMorph software and displayed using Corel Draw X5.
Statistics
Results are mean 6 SD of at least 3 independent experiments.
For experiments assessing rab11a mediated trafficking of PAR2
and degradation of PAR2, statistical significance was assessed
using a 2-way ANOVA test. All other experiments were assessed
by Student’s t test. P,0.05 was considered significant.
Results
Inhibition of palmitoylation reduces cell surface
expression of endogenous PAR2
Shown in Figure 1A is an alignment of amino acids from
transmembrane domain 7 to the carboxyl terminal of two known
palmitoylated GPCRs, vasopressin V2 receptor (V2R) [41] and
Figure 2. PAR2 is palmitoylated on cysteine 361. A, Anti-myc and anti-GAPDH Western blot analysis of lysates from CHO cells stably expressing
either vector, PAR2-myc or PAR2-C361A-myc. Before collection of lysates cells were either untreated or treated with the N-glycosylation inhibitor
tunicamycin. *, non-specific band. B, Analysis of PAR2 palmitoylation using acyl-biotinyl exchange chemistry. Membrane fractions were collected from
CHO-PAR2-myc and CHO-PAR2-C361A-myc cells either untreated or treated with 2-bromopalmitate (2BP) for 16 h. Free thiols on membrane proteins
were blocked with NEM, endogenous palmitoyl groups were removed using hydroxylamine followed by sulphydryl-reactive biotinylation of liberated
cysteines. Biotinylated proteins were isolated by streptavidin beads, eluted and subjected to anti-myc Western blot analysis to examine PAR2
palmitoylation. C, Analysis of PAR2 palmitoylation by examining cells metabolically labelled with an alkyne containing palmitate analogue (17-ODYA)
followed by click chemistry. PAR2-myc and PAR2-C361A-myc CHO cells were incubated with 2-bromopalmitate for 16 h and cerulenin (5 mg/mL) for
1 h then labelled with 17-ODYA for 4 h, before collection of membrane preparations and reaction of biotin-azide to 17-ODYA labelled proteins via
click chemistry. Biotinylated proteins were isolated using streptavidin beads and PAR2 palmitoylation was assessed by anti-myc Western blot analysis
from bead elutes. D, Analysis of whether palmitoylation of PAR2 occurs exclusively on a cysteine residue and not via an amide linkage. Membrane
preparations were collected from CHO-PAR2-myc and CHO-PAR2-C361A-myc 17-ODYA labelled cells. Labelled proteins were reacted with biotin-
azide via click chemistry before incubation with 0.7 M hydroxylamine (H) to cleave thioester linkages or 50 mM tris pH 7.4 (T; control). Biotinylated
proteins were isolated using streptavidin beads and PAR2 palmitoylation was assessed by anti-myc Western blot analysis from bead elutes. E,
Comparison of intracellular Ca
2+ mobilisation mediated by trypsin activation of PAR2-myc (#, EC50 5.360.5 nM) and PAR2-C361A-myc (%, EC50
44.360.8 nM) in stably expressing CHO cells. Experiments were performed in triplicate on 3 separate occasions and values are Mean +/2 SD.
doi:10.1371/journal.pone.0028018.g002
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PAR family. Recently Botham and co-workers have demonstrated
that C361 of PAR2 (Fig. 1A schematic), which aligns with the
palmitoylation sites of V2R (a di-cysteine) and b2R (a mono-
cysteine), is the primary palmitoylation site of the GPCR PAR2 in
over-expressing CHO-Pro5 cells [21]. For the purpose of
examining the role of palmitoylation in PAR2 cell surface
localization in endogenous expressing cells, we first examined
the ability of anti-PAR2 antibodies, SAM11 and N19, to detect
PAR2. As shown in Figure 1B, Western blot analysis showed that
both antibodies detect PAR2 as a smear from ,35 to ,150 kDa
in lysates from stably expressing CHO cells. However, non-specific
signals were also apparent with both antibodies (Fig. 1B, vector
lanes) indicating that these would not be ideal for Western blot
based approaches to evaluate PAR2 palmitoylation. In contrast,
flow cytometry analysis indicated that both antibodies specifically
detect PAR2 expressed on the surface of stably expressing CHO
cells with no evidence of non-specific binding apparent from
staining of CHO-vector cells (Fig. 1C). Flow cytometry analysis of
prostate cancer PC-3 cells, that are known to endogenously
express PAR2 [12], indicated that both antibodies can detect the
endogenous receptor (Fig. 1D). As the signal with the N19
antibody was stronger, this antibody was used in flow cytometry
assays to examine the role of palmitoylation in cell surface
expression of PAR2 in PC-3 cells and two other endogenous
expressing prostate cancer lines, DU145 and 22Rv1. As
palmitoyaltion is known to impact on cell surface localization of
other GPCRs [25], we evaluated the effect of the palmitoylation
inhibitor 2-bromopalmitate, on the plasma membrane location of
PAR2 expressed by these three cell lines. This inhibitor functions
by inhibiting the enzymes required for palmitoylation, palmitoyl
acyltransferases (PATs; [38]), and as shown in Figure 1E, reduced
cell surface expression of PAR2 in each cell line by ,50%. These
data suggest that endogenous PAR2 is likely palmitoylated in PC-
3, DU145 and 22Rv1 cells.
Characterisation of palmitoylation deficient PAR2 stably
expressed by CHO cells
To directly examine the mechanisms regulating palmitoylation
of PAR2 and the role of this palmitoylation in PAR2 signalling
and trafficking, we generated CHO-K1 cells stably expressing
PAR2-C361A-myc. As shown in Figure 2A, anti-myc Western blot
analysis showed that this mutant PAR2 is expressed at similar levels
to the wildtype protein in stably expressing CHO cells. In addition,
Western blot analyses of lysates collected from these cells treated
with the N-glycosylation inhibitor tunicamycin, indicated that
wildtype PAR2 and the receptor mutated at C361 each carry
similar levels of N-linked glycans (Fig. 2A). These cells were used in
two approaches to assess palmitoylation of PAR2 at C361. In the
first approach, employing ABE chemistry, free cysteines on proteins
from membrane preparations were first blocked using NEM.
Cysteine-palmitoyl thioester bonds were then specifically cleaved
using the weak nucleophile hydroxylamine which breaks these
bonds but not amide-palmitoyl linkages [23]. Liberated cysteines
were then reacted with sulfhydryl reactive EZ-link HPDP-biotin to
label proteins that had originally contained palmitoyl moieties.
Biotinylated proteins were isolated using streptavidin beads and the
level of palmitoylated PAR2 present in this fraction was assessed by
anti-myc Western blot analysis. This method assesses the gross
amount of PAR2 palmitoylation. As shown in Figure 2B, PAR2-
myc was detected as a smear ranging from ,35 kDa to ,150 kDa
indicating that this protein is palmitoylated. Consistently, this
Western blot analysis also showed that the palmitoylation inhibitor
2-bromopalmitate completely blocked palmitoylation of PAR2. In
contrast with wildtype PAR2, the C361 mutant was not
pamitoylated in the presence or absence of 2-bromopalmitate.
In the second approach, using click chemistry, PAR2-myc and
PAR2-C361A-myc CHO cells were treated with an inhibitor of
endogenous palmitate synthesis, cerulenin, before metabolic
labelling with the alkyne containing palmitate analog 17-ODYA.
Membrane preparations were collected and biotin-azide reacted to
17-ODYA labelled proteins via copper catalysed alkyne-azide
cycloaddition (click) chemistry. Biotinylated proteins were isolated
using streptavidin beads and PAR2 palmitoylation was detected
from bead elutes by anti-myc Western blot analysis. Whereas ABE
chemistry examines gross whole proteome palmitoylation, meta-
bolic labelling of live cells with a palmitate analogue, while
blocking endogenous palmitate synthesis, followed by reaction
with biotin-azide via click chemistry enables identification of
dynamically palmitoylated proteins [43]. As shown in Figure 2C,
this approach confirmed that wildtype but not C361A PAR2 is
palmitoylated and that palmitoylation of wildtype PAR2 is
blocked by the palmitoylation inhibitor 2-bromopalmitate. To
confirm that palmitoylation of PAR2 occurs exclusively on a
cysteine residue, and not via an amide linkage that can sometimes
occur [44], we treated biotinylated proteins with the weak
nucleophile hydroxylamine or, as a negative control, Tris, before
isolation of proteins containing biotin using streptavidin beads. In
contrast with the ABE chemistry approach which is not capable
of detecting amide-palmitate linkages, this modification to our
click chemistry protocol permits the distinction between S-
palmitoylation and N-palmitoylation. As shown in Figure 2D,
hydroxylamine but not Tris treatment completely removed all
palmitoylation of PAR2 indicating that this receptor is exclusively
palmitoylated on a cysteine residue. Consistent with the report of
Figure 3. Palmitoylation of PAR2 at C361 is required for
efficient cell surface receptor localization. A, Images of CHO cells
transiently co-transfected for 12 h with PAR2-mCherry (red) and PAR2-
GFP (green). The merge image shows colocalization (yellow) of these
two proteins. B, Images of CHO cells transiently co-transfected for 12 h
with PAR2-mCherry and PAR2-C361A-GFP. The merge image shows
colocalization (yellow) of these two proteins and regions where only
PAR2-mCherry is expressed (red). Cells were analysed using a Zeiss
LSM510 confocal microscope (636 oil immersion objective lens) and
images were processed using MetaMorph software and displayed using
CorelDraw X5. Images of cells are representative of three independent
experiments. Scale bar,1 0mM.
doi:10.1371/journal.pone.0028018.g003
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palmitoylated at C361. Our data also indicate that this is the
exclusive site at which PAR2 is palmitoylated.
We performed Ca
2+ mobilisation assays to examine the effect of
mutation of PAR2 C361 on signal transduction initiated via
cleavage of this receptor by trypsin. As shown in Figure 2E, in
response to trypsin PAR2-C361-myc was ,9 fold less potent than
PAR2-myc (half-maximal response (EC50) of 44.3 versus 5.3 nM)
with a reduction of about 33% in the maximum signal induced via
the mutant receptor. These data are comparable with the findings
of Botham et al. (PAR2 EC50 11.4 nM and PAR2-C361A EC50
40.8 nM) and indicate that palmitoylation of C361 is essential for
efficient PAR2 signal transduction [21].
Palmitoylation of PAR2 at C361 is required for efficient
cell surface receptor localization
To examine whether the reduced signalling efficiency of PAR2-
C361A is due to a reduction in the level of PAR2 expressed on the
plasma membrane, we analysed the localization of wildtype and
mutant PAR2 expressed by CHO cells. Confocal microscopy was
performed on CHO cells transiently co-transfected with wildtype
PAR2-mCherry and PAR2-GFP or wildtype PAR2-mCherry and
PAR2-C361A-GFP. As indicated by the yellow signal from the
merged images shown in Figure 3A, wildtype PAR2-GFP (green)
and PAR2-mCherry (red) co-localised throughout subcellular
compartments and the plasma membrane. In contrast, PAR2-
C361A-GFP (green) co-localised with wildtype PAR2-mCherry
(red) in large perinuclear compartments (yellow in merged image)
but not at the cell surface where signal was predominantly from
wildtype PAR2 (Fig. 3B, red signal in merged image). These data
contrast with the findings of Botham and co-workers who showed
by flow cytometry that PAR2-C361A is expressed at higher levels
than PAR2 on the surface of stably expressing by CHO-Pro5 cells.
However, our qualitative data from confocal microscopy analysis
were confirmed by quantitative analysis using flow cytometry and
cell surface biotinylation assays. As shown in Figure 4A, flow
cytometry analysis using anti-PAR2 antibody N19 indicated that
PAR2-C361A levels on the cell surface were ,70% lower than
wildtype PAR2 levels. The effect of C361 mutation on cell surface
expression of PAR2 was about the same as 2-brompalmitate
inhibition of palmitoylation of PAR2 (Fig. 4A). We obtained
consistent data by examining plasma membrane expression of
Figure 4. Quantitative analysis of the effect of palmitoylation on cell surface expression of PAR2. A, Anti-PAR2 N19 antibody flow
cytometry analysis of non-permeabilised CHO-PAR2-myc and CHO-PAR2-C361A-myc cells treated with either DMSO (negative control) or 2BP for
16 h. Secondary antibody only MFI values were subtracted from N19 values and these are shown relative to values from CHO-vector untreated cells.
Values were determined from 3 independent experiments and are shown as Mean 6 SD. B, (Left panel) Examination of plasma membranePAR2 levels
by cell surface biotinylation. Live cells were reacted with membrane impermeant EZ-link NHS-SS-biotin. Plasma membrane (PM) and intracellular (IC)
fractions were collected from whole cell lysates and subjected to anti-myc, anti-GAPDH (control for IC fraction) and anti-b1 integrin (control for PM
fraction) Western blot analysis. The data are representative of 3 independent experiments. (Right panel) Graphical representation of densitometric
analysis of data from these 3 experiments. Values of PM PAR2 were normalised to b1 integrin signal and are displayed as Mean 6 SD. C, Anti-PAR2
N19 antibody flow cytometry analysis of DU145 cells transiently transfected with vector, PAR2-GFP or PAR2-C361A-GFP. MFI values from 3
independent experiments were used to calculate fold change of cell surface PAR2 and PAR2-C361A relative to vector transfected cells and are
displayed as Mean 6 SD. **, P,0.05; ***, P,0.001.
doi:10.1371/journal.pone.0028018.g004
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anti-myc Western blot analysis of intracellular (IC) and plasma
membrane (PM) fractions collected from cell surface biotinylated
CHO-vector, CHO-PAR2-myc and CHO-PAR2-C361A-myc cells
showed much lower levels of PAR2-C361-myc in the PM fraction
compared with PAR2-myc. Graphical representation of signals
obtained from 3 independent experiments showed that cell surface
levels of PAR2-C361-myc were 71.664.4% lower than PAR2-myc
(Fig. 4B, right). To examine if palmitoylation of PAR2 C361 is
required for efficient cell surface expression of PAR2 in an
endogenous expressing cells, we transiently transfected DU145 cells
with expression constructs encoding wild type PAR2 or palmitoyla-
tiondeficient PAR2-C361A and followed surface expression by flow
cytometry. For this experiment we used anti-PAR2 antibody N19
that will detect both endogenous PAR2 as well as transiently
expressed PAR2-myc. As shown in Figure 4C, after subtracting the
level of endogenous cell surface PAR2 (identified from DU145-
vector cells), DU145 cells transiently expressing C361 PAR2
exhibited 63.961.4% less cell surface PAR2 compared with cells
transiently expressing wild type receptor. Together these data
indicate that palmitoylation of PAR2 at C361 is required for
efficient plasma membrane localization of this receptor.
PAR2 agonism stimulates palmitate incorporation which
occurs during secretory trafficking in pre-medial Golgi
vesicles
To understand mechanisms resulting in the reduced signalling
efficiency and cell surface expression of PAR2-C361A-myc, we
examined the effect of agonist stimulation (PAR2 AP SLIGRL-
NH2) on palmitoylation of wildtype and C361A PAR2 and the
intracellular location where palmitoylation occurs. We used
metabolic labelling followed by click chemistry mediated biotin
labelling of proteins, as described above, to examine the effect of
agonism on PAR2 palmitoylation. Membrane fractions were
collected from cells metabolically labelled with 17-ODYA in
the presence or absence of AP for 40 and 120 min. As shown in
Fig.5A, anti-mycWestern blot analysis indicated that incorporation
of palmitate in untreated cells increased moderately between 40 and
120 min whereas PAR2 AP caused a significantly larger increase in
palmitoylation over this period. These data suggest that PAR2
palmitoylation is induced by receptor agonism.
To examine the subcellular site at which PAR2 palmitoylation
occurs, CHO-PAR2-myc cells were labelled with 17-ODYA for
2 h in the presence or absence of PAR2 AP and three different
drugs known to reduce protein trafficking through the endoplas-
mic reticulum (ER) and Gogli organelles: brefeldin A treatment
collapses the Golgi apparatus leading to protein accumulation in
the ER [36], nocodazole inhibits microtubule formation prevent-
ing ER to Golgi transport, leading to protein accumulation in late
ER/early Golgi vesicles [37] and monensin impedes protein
trafficking leading to accumulation in the medial-Golgi apparatus
[36]. Biotin-azide was reacted with equal amounts of 17-ODYA
labelled membrane proteins via click chemistry and biotinylated
proteins were isolated using streptavidin beads and PAR2
palmitoylation examined by anti-myc Western blot analysis from
bead elutes. As shown in Figure 5B (vehicle), agonism induced
robust PAR2 palmitoylation in vehicle treated cells and this was
blocked in cells treated with brefeldin A (BFA) and nocodazole
(NOC) indicating that palmitoylation of this receptor occurs after
the ER. In contrast, PAR2 palmitoylation was still apparent in
monensin treated cells (MON) indicating that this receptor is
palmitoylated in pre-medial Golgi vesicles. These data suggest that
PAR2 is palmitoylated in response to agonism during transport
through sub-compartments of the Golgi apparatus prior to
receptor transport to the cell surface.
Palmitoylation of PAR2 is required for efficient rab11a-
mediated receptor repopulation of the cell surface in
response to agonist stimulation
Rab11a, a guanosine triphosphatase (GTPase), regulates
exocytic membrane traffic and fusion [45,46] and enhances
Figure 5. PAR2 agonism stimulates palmitate incorporation
which occurs during secretory trafficking in pre-medial Golgi
vesicles. A, CHO-PAR2-myc cells preincubated with cerulenin for 1 h
were labelled with 17-ODYA for 1.5 h in the presence or absence of
PAR2-AP (100 mM) for the indicated times. Membrane preparations
were collected and biotin-azide reacted to 17-ODYA labelled proteins
via click chemistry. Biotinylated proteins were isolated using strepta-
vidin beads. PAR2 palmitoylation was assessed by anti-myc Western
blot analysis of bead elutes. B, CHO-PAR2-myc cells preincubated with
cerulenin were labelled with 17-ODYA for 2 h in the presence or
absence of PAR2 AP (100 mM). Nocodazole (20 mg/mL; NOC) was added
to medium 15 min prior to labelling with 17-ODYA and monensin
(10 mM; MON) and brefeldin A (5 mg/mL; BFA) were added to medium
30 min prior to labelling with 17-ODYA. Labelled proteins were reacted
to biotin-azide via click chemistry and biotinylated proteins isolated
using streptavidin beads. Palmitoylated PAR2 was detected by anti-Myc
Western blot analysis of bead elutes. Data shown in B is from cropped
lanes from a single Western blot analysis. The data are representative of
three independent experiments.
doi:10.1371/journal.pone.0028018.g005
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palmitoylation is required for agonist stimulated rab11a mediated
PAR2 transport to the plasma membrane, we performed antibody
N19 flow cytometry analysis of CHO-PAR2-myc and PAR2-
C361A-myc cells. These cells were transiently transfected with
vector, rab11a-GFP or dominant negative mutant rab11a-S25N-
GFP and treated in suspension with trypsin (50 nM) for 15 min
before removal of trypsin and monitoring of cell surface expressed
PAR2 after 15 and 30 min. As shown in Figure 6, levels of cell
surface PAR2-myc in vector transfected cells steadily increased in
response to trypsin agonism, indicating that the cell surface was
being replenished with nascent receptor. Consistent with
previous reports [19], wild type rab11a significantly increased
cell surface localization of PAR2 and this effect was slowed by
dominant negative rab11a-S25N. Consistent with data in
Figure 3 and 4, PAR2-C361A-myc trafficked to the cell surface
but at a much lower rate that wildtype receptor (Fig. 6, PAR2-
C361A+Vector). In addition, replenishment of the cell surface
with this mutant receptor was almost unaffected by rab11a-
S25N. However, we note that rab11a induced a statistically
significant increase (P,0.05) in cell surface PAR2-C361A-myc in
response to receptor agonism (Fig. 6). These data indicate that
rab11a-mediated trafficking of PAR2 to the cell surface in
response to agonism is largely palmitoylation dependent and that
there is a smaller, but appreciable, palmitoylation independent
component.
Mutation of PAR2 C361 alters agonist-induced
recruitment of b-arrestin-1 and b-arrestin-2
b-arrestin-1 and -2 are rapidly recruited to the carboxyl
terminus of PAR2 following receptor activation, leading to rapid
internalisation [14,47]. To assess the impact of PAR2 palmitoyla-
tion on receptor desensitisation, we examined PAR2 agonist-
induced b-arrestin-1 and -2 recruitment by confocal microscopy.
CHO cells were transiently co-transfected with b-arrestin-1-GFP
or b-arrestin-2-GFP with wildtype PAR2-mCherry or PAR2-
C361A-mCherry. As shown in Figure 7A, b-arrestin-1-GFP and
b-arrestin-2-GFP localise throughout the cytoplasm of untreated
cells co-transfected with either wild type or palmitoylation-
deficient PAR2-mCherry. Stimulation of wild type PAR2 with
AP for 5 min induced rapid translocation of b-arrestin-1-GFP and
b-arrestin-2-GFP to the plasma membrane and colocalization with
PAR2 that was sustained for at least 15 min (Fig. 7A, yellow in
merged images). In contrast, b-arrestin-1-GFP remained localised
to the cytoplasm of cells expressing PAR2-C361A-mCherry under
agonist-induced conditions at both time points (Fig. 7B, left).
However, agonist stimulation of PAR2-C361A-myc induced a
delayed relocation of b-arrestin-2-GFP to the plasma membrane
(Fig. 7B, right, yellow in merged image at 15 min). These data
suggest that PAR2 palmitoylation is essential for agonist induced
relocation of b-arrestin-1 to the cell surface but not for relocation
of b-arrestin-2.
PAR2 C361 is required for efficient agonist-induced
receptor endocytosis and degradation
Our data indicate that compared with wildtype receptor, PAR2-
C361A displays reduced trafficking to the cell surface, lower levels
of plasma membrane localization and diminished b-arrestin
recruitment following receptor agonism. As it has previously been
reported that after b-arrestin recruitment, agonism of PAR2
results in rapid receptor internalisation and sorting for lysosomal
degradation [14–46], we evaluated the effect of loss of palmitoyla-
tion on the rate of endocytosis and degradation of this receptor. To
assess endocytosis, we examined the rate of agonist-induced
internalisation of wildtype and C361A PAR2. CHO cells stably
expressing wildtype PAR2-myc or PAR2-C361A-myc labelled
with biotin were treated with PAR2 AP (100 mM) for 5, 15 and
30 min to allow endocytosis. After these periods of internalisation,
residual cell surface biotin was removed by washing cells with
MeSNA. Endocytosed proteins labelled with biotin were isolated
from whole cell lysates using streptavidin beads and the level of.
PAR2 endocytosis examined from bead elutes by anti-myc
Western blot analysis. As shown in Figure 8A, PAR2-myc
endocytosis steadily increased over 30 min in response to PAR2
AP with the internalised receptor detected following 5 min and
maximal PAR2 endocytosis detected at 15 min. In contrast, under
the same conditions, internalisation of PAR2-C361A-myc was
greatly reduced (Fig. 8A). Graphical analysis of densitometric
Figure 6. Palmitoylation of PAR2 is required for efficient rab11a-mediated repopulation of the cell surface in response to agonist
stimulation. CHO-PAR2-myc and CHO-PAR2-C361A-myc cells transiently transfected with vector, rab11a-GFP or dominant negative rab11a-S25N-
GFP were treated with 50 nM trypsin for 15 min to remove cell surface PAR2. Cells were then washed and incubated with trypsin-free DMEM for the
indicated times to allow repopulation of PAR2 at the cell surface. Plasma membrane PAR2 was measured by flow cytometry using the anti-PAR2 N19
antibody. MFI values were used to calculate percentage of cell surface PAR2 relative to vector cells. Experiments were performed in triplicate on 3
independent occassions. Data are displayed as mean 6 SD. Statistical significant differences - 30 min: PAR2+vector 36.861.6%, PAR2+rab11a-GFP
65.5%, P,0.0001; PAR2-C361A+vector 22.763.5%, PAR2-C361A+rab11a-GFP 33.464.0%, P,0.05; PAR2-C361A+rab11a-GFP 33.464.0%, PAR2+-
rab11a-GFP 65.5%, P,0.0001, compared with PAR2-C361A+rab11a-GFP.
doi:10.1371/journal.pone.0028018.g006
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total cell surface PAR2 indicated that mutation of C361 reduced
the level of PAR2 internalisation by approximately 50% (Fig. 8A).
These data indicate that palmitoylation is required for efficient
agonist-induced PAR2 endocytosis.
To assess receptor degradation CHO-PAR2-myc and CHO-
PAR2-C361A-myc cells, treated with cycloheximide to inhibit de
novo protein synthesis, were incubated with PAR2 AP. As shown in
Figure 8A, anti-myc Western blot analysis indicated that PAR2-
myc levels dropped markedly over a 4 h period following AP
treatment. In contrast, under the same conditions the reduction in
PAR2-C361A-myc levels was much less pronounced (Fig. 8 B).
Graphical analysis of densitometric analysis of three independent
Western blot analyses indicated that 4 hours after AP treatment
levels of PAR2-myc dropped by 9064.5% whereas PAR2-C361A-
myc reduced by 22.662.4% (P,0.0001, compared with PAR2-
myc) (Fig. 8B). These data indicate that loss of palmitoylation
reduces the rate of degradation of PAR2 in response to agonist
stimulation.
Discussion
We have examined the role of palmitoylation in trafficking to
and from the cell surface of the protease activated GPCR PAR2 as
well as the effect of this post-translational modification on receptor
signalling. Our data extend findings from a recent report by
Botham and colleagues [21] who demonstrated that palmitoyla-
tion of PAR2 can occur at C361. However, in several respects our
data are also inconsistent with a number of the key results of this
group. We show for the first time that inhibition of palmitoylation
reduces the cell surface localization of PAR2 by at least 50% in
endogenous expressing cell lines (PC3, DU145 and 22Rv1). We
also show that PAR2-C361A transiently expressed by one of these
endogenous expressing cells lines (DU145) is inefficiently trafficked
to the cell surface compared with wildtype PAR2. These data
suggest that palmitoylation is required for efficient plasma
membrane expression of endogenously expressed PAR2. This
conclusion is the converse of the findings of Botham et al. who
showed by flow cytometry that palmitoylation-deficient PAR2,
Figure 7. Mutation of PAR2 C361 alters agonist-induced recruitment of b-arrestin-1 delays b-arrestin-2. Confocal microscopy analysis of
untreated live cells and at 5 and 15 min after agonism with PAR2 AP (100 mM). A, CHO cells transiently co-expressing PAR2-mCherry (red) and b-
arrestin-1-GFP (green) or b-arrestin-2-GFP (green). The merge image highlights colocalization (yellow) of PAR2 and b-arrestins. B, CHO cells transiently
co-expressing PAR2-C361A-mCherry (red) and b-arrestin-1-GFP (green) or b-arrestin-2-GFP (green). The merge image highlights colocalization
(yellow) of PAR2 and b-arrestins. Cells were analysed using a Zeiss LSM510 confocal microscope (636oil immersion objective lens) and images were
processed using MetaMorph software and displayed using CorelDraw X5. Images of cells are representative of three independent experiments. Scale
bar,1 0mM.
doi:10.1371/journal.pone.0028018.g007
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membrane at between ,150% (70% confluence) and ,175%
(20% confluence) of the levels of wildtype PAR2 [21]. However,
our data are supported by flow cytometry and cell surface
biotinylation studies of wildtype and C361A PAR2 stably
expressed by CHO-K1 cells as well as of confocal microscopy
analysis of transiently transfected cells. In addition to demonstrat-
ing that PAR2 is exclusively palmitoylated at C361, these
approaches showed, consistent with our observations from
endogenous expressing cells, that mutation of C361 results in at
least a 60% reduction in the cell surface expression of PAR2.
As depicted in Figure 9, our data indicate that palmitoylation of
PAR2 is required for optimal receptor signalling, cellular
trafficking and plasma membrane expression. We propose that
mono-palmitoylation of PAR2 at C361 occurs in the Golgi
apparatus prior to transit to the medial-Golgi and this is enhanced
by receptor agonism at the cell surface. Efficient cell surface
repopulation of PAR2 by the GTPase rab11a is also dependent on
receptor palmitoylation and in its absence, nascent PAR2
accumulates in pre-Golgi vesicles or the early Golgi, preventing
efficient trafficking toward the plasma membrane. Our calcium
flux data indicate that palmitoylation is also required for efficient
PAR2 signalling via Gaq. However, we note that the observed
reduction in Gaq signalling via PAR2-C361A compared with
wildtype receptor is likely largely due to the reduced expression of
PAR2 on the cell surface. It has previously been shown that
receptor activation induces translocation of b-arrestin from the
cytosol to the plasma membrane to facilitate non-G protein
mediated signal transduction and PAR2 internalisation [14,47].
However, agonism of cells expressing palmitoylation-deficient
PAR2 fails to induce b-arrestin-1 translocation while b-arrestin-2
translocation is delayed. As our confocal, flow cytometry and cell
surface biotinylation assays indicated that palmitoylation deficient
PAR2 is capable of trafficking to the plasma membrane, albeit
with reduced efficiency compared with wildtype receptor, the
observed effects on b-arrestins suggest that palmitoylation is
required for efficient internalisation of PAR2. This was supported
by assays showing that endocytosis of this receptor is markedly
reduced when C361 is mutated. Consistently, degradation of
PAR2-C361A following receptor agonism occurs at much lower
levels than wildtype PAR2, likely because lower levels of the
mutated receptor are trafficked to the cell surface and available for
activation. Thus, our model suggests that palmitoylation of PAR2,
induced by cell surface agonism, is required for efficient trafficking
from Golgi stores to the plasma membrane. At this location,
palmitoylation is also required for efficient recruitment of proteins
that are needed for signal transduction, receptor desensitisation
and internalisation and sorting for lysosomal degradation.
Accordingly, these data suggest that palmitoylation is an essential
post-translational modification in the lifecycle of PAR2.
Figure 8. PAR2 C361 is required for efficient agonist-induced receptor endocytosis and degradation. A, CHO-PAR2-myc and CHO-PAR2-
C361A-myc cells labelled with membrane impermeant EZ-link NHS-SS-biotin were treated with PAR2 AP (100 mM) for the indicated times to induce
receptor internalisation. Protein degradation was blocked by incubation of cells with the proteasome inhibitor MG132. Residual cell surface biotin
was removed by washing with MeSNA and internalised biotin-labelled protein was isolated from whole cell lysates using streptavidin beads. Anti-myc
Western blot analysis was performed on bead eluates and input lysates. Data are representative of 3 independent experiments with graphical
representation of densitometry analysis of these data shown in the right panel. Percentage of internalised receptor was calculated by dividing the
value for internalised PAR2 at each time point by the value for total surface PAR2 which was determined from an experiment performed in parallel in
which cells were not treated with AP or MeSNA. Values are displayed as Mean 6 SD. B, CHO-PAR2-myc and CHO-PAR2-C361A-myc cells were treated
with PAR2 AP (100 mM) for the indicated times in the presence of 70 mM cycloheximide, to prevent de novo protein synthesis. Lysates were examined
by anti-myc and anti-GAPDH Western blot analysis to assess the levels of PAR2 remaining after receptor agonism. Data are representative of 3
independent experiments with graphical representation of densitometry analysis of these data shown in the right panel. Values are displayed as
Mean 6 SD. PAR2 endocytosis and degradation were significant compared with PAR2-C361A; P,0.001.
doi:10.1371/journal.pone.0028018.g008
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export and during Golgi transit is consistent with the observation
that 12 of the 23 known human PATs are located within the Golgi
apparatus [48,49]. In addition, several other proteins are
palmitoylated at this site including endothelial nitric oxide
synthase [49], tetraspanins CD9 and CD151 [50,51,52]. Further-
more, several GPCRs are palmitoylated during transport from
ER-Golgi intermediate compartments through to the medial Golgi
including CCR5 [53,54], d-opioid receptor [55], thyrotropin
receptor [56] and vasopressin V1a receptor [57]. Further work is
required to identify the PAT(s) that palmitoylate PAR2 within the
Golgi apparatus. In addition, based on the diverse localization of
PATs within cells and the dynamic nature of S-palmitoylation, it is
possible that PAR2 will be palmitoylated at other cellular locations
as occurs for the d-opioid receptor [55] and the b1-adrenergic
receptor [58].
The palmitoylation of Golgi localised PAR2 in response to
receptor agonism and prior to cell surface expression, suggests that
this modification facilitates plasma membrane targeting. In
support of this, the palmitoylation inhibitor 2-bromopalmitate
reduced cell surface expression of both endogenous and over-
expressed PAR2. Moreover, PAR2-C361A, although capable of
trafficking to the cell surface, displayed greatly reduced plasma
membrane localization. Consistent with these observations, other
GPCRs and membrane receptors also display reduced cell surface
expression following chemical inhibition of palmitoylation or
mutation of carboxyl terminal palmitoylation sites. These include
the chemokine CCR5 receptor [53,54], dopamine D1 receptor
[59], follicle-stimulating hormone receptor [60], histamine H2
[61], lutropin/choriogonadotropin receptor [62], d-opioid recep-
tor [55], V2R [41,63]. In addition, we note that there are
examples of GPCRs (V1a vasopressin receptor, b1R and b2R) that
show unaffected cell surface expression when palmitoylation is
blocked [42,57,58]. Accordingly, the proposal by Botham and
colleagues that mutation of the PAR2 palmitoylation site results in
elevated cell surface expression [21] should be viewed with
caution. It is not clear why the data of these workers differ from
our own findings, although it is possible that use of different CHO
cell sub-lines may be a contributing factor. Whereas we used
CHO-K1 cells, Botham and colleagues employed the CHO-Pro5
line which is the parental cell line for several glycosylation
defective sub-lines and an auxotroph requiring proline supple-
mentation [64].
Several years ago the crystal structure of the class A GPCR
bovine rhodopsin revealed that a partially exposed a-helix,
designated a-helix 8 (a-H8), is located between the final
transmembrane domain and the palmitoylated cysteines in the
carboxyl terminus of this receptor [65]. Since then this domain has
been identified in other GPCRs containing consensus carboxyl
terminal palmitoylation sites including cannabinoid receptor 2,
b2R, adrenoreceptor [66], cannabinoid receptor 1 [67] and b1-
adrenergic receptor [26]. It is clear from our study and the report
of Botham et al. [21] that C361 of PAR2 is palmitoylated and this
modification is at the carboxyl boundary of a putative PAR2 a-
H8. These domains have been shown to be required for direct
coupling of several GPCRs with G protein subunits
Figure 9. PAR2 palmitoylation is required for optimal receptor signalling, cellular trafficking and plasma membrane expression.
Unpalmitoylated PAR2 located in Golgi vesicles (1). Palmitoylation occurs within the cis- to medial-Golgi (2). This anchors the carboxyl domain of
PAR2 to the inner leaflet of cell membranes likely resulting in the formation of an intracellular eighth a-helix (H8) required for effective signalling (2).
Interactions of palmitoylated PAR2 with the GTPase rab11a promotes agonist induced receptor repopulation of the cell surface (3). Activation of PAR2
(4) enhances palmitoylation of Golgi localised PAR2 (5) and, reciprocally, receptor palmitoylation is required for efficient PAR2 signal transduction (6).
Receptor agonism induces b-arrestin translocation to the plasma membrane (7) which mediates non-G protein signal transduction and receptor
internalisation (8). Internalised PAR2 is trafficked and sorted for lysosomal degradation via early and late endosomes (9).
doi:10.1371/journal.pone.0028018.g009
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switches between inactive (helical) and active (non-helical) in
response to ligand binding. Very recently the a-H8 of PAR1 was
shown to be critical for Gq-dependent receptor signalling [28] and
the direct relevance of this domain to PAR2 signalling is suggested
by the observation that its deletion completely prevents Gaq signal
transduction [71]. Accordingly, it is possible that like other
GPCRs, PAR2 palmitoylation contributes to a-H8 stability
thereby enabling efficient G protein coupling. In addition, it is
possible that PAR2 palmitoylation-induced stabilization of its a-
H8 is required for rab11a-mediated receptor repopulation of the
cell surface in response to agonist stimulation. This is based on the
observation that palmitoylation stabilises the a-H8 of the
prostacyclin receptor and this is required for its interactions with
rab11a during receptor internalization and recycling [72].
Consistently, we observed that whereas agonist-induced cell
surface localization of wildtype PAR2 was significantly increased
by rab11a, replenishment of the cell surface with mutant receptor
was almost unaffected by this GTPase. Thus, although we did not
address this possibility experimentally, the PAR2 a-H8 may
mediate any direct interactions between receptor and rab11a
allowing efficient transport to the plasma membrane.
Our results indicate that mutation of the PAR2 palmitoylation
site also negatively impacts on agonist-induced b-arrestin coloca-
lization with this receptor at the plasma membrane. Similar effects
on b-arrestin recruitment have been reported for the GPCRs V2R
[73] and TRH receptor [74]. Interestingly, palmitoylation has
been shown to alter phosphorylation of the GPCRs 5-hydroxy-
tryptamine4a receptor [75], b2R [42], CCR5 [76], TRH receptor
[77] and vasopressin V1a receptor [57] and of the AMPA
membrane receptor GluR1 [78]. Accordingly, as it is known that
phosphorylation of the PAR2 carboxyl tail is a key regulator of b-
arrestin recruitment to this receptor [15], we speculate that
palmitoylation is a necessary prerequisite for the phosphorylation
that is essential for b-arrestin recruitment to PAR2.
In summary, these data provide new insights on the role of
palmitoylation in the life cycle of PAR2. The data indicate that
this post-translational modification is required for maximal cell
surface expression of endogenous and stably expressed PAR2 and
is needed for both efficient signalling and agonist-induced rab11a-
mediated PAR2 trafficking to the plasma membrane. At the
plasma membrane agonist-induced b-arrestin recruitment is
compromised by mutation of the PAR2 palmitoylation site as is
receptor degradation in response to agonism. We also note that
loss of palmitoylation does not completely block these PAR2
cellular processing events. Accordingly, further studies are
required to examine other mechanisms regulating this receptor.
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